Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Net Income: 2020-2025

Historic Net Income for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$16.5 million.

  • Foghorn Therapeutics' Net Income rose 13.87% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 17.80%. This contributed to the annual value of -$86.6 million for FY2024, which is 11.99% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Net Income stood at -$16.5 million for Q3 2025, which was up 12.34% from -$18.8 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Net Income peaked at -$14.3 million during Q3 2023, and registered a low of -$30.5 million during Q1 2023.
  • Over the past 3 years, Foghorn Therapeutics' median Net Income value was -$20.2 million (recorded in 2025), while the average stood at -$21.9 million.
  • In the last 5 years, Foghorn Therapeutics' Net Income slumped by 68.90% in 2021 and then soared by 44.33% in 2023.
  • Foghorn Therapeutics' Net Income (Quarterly) stood at -$28.5 million in 2021, then dropped by 1.33% to -$28.9 million in 2022, then grew by 16.55% to -$24.1 million in 2023, then increased by 19.09% to -$19.5 million in 2024, then rose by 13.87% to -$16.5 million in 2025.
  • Its last three reported values are -$16.5 million in Q3 2025, -$18.8 million for Q2 2025, and -$20.2 million during Q1 2025.